Biopharmaceutical company developing therapeutic antibody medicines using its proprietary Humaneering antibody-engineering platform
Biopharmaceutical company developing therapeutic antibody medicines using its proprietary Humaneering antibody-engineering platform. Its pipeline included antibody candidates for rheumatoid arthritis and other autoimmune diseases, Pseudomonas aeruginosa infections, and later lenzilumab for a rare blood cancer.